Biomarkers

 I. SCOPE AND METHODOLOGY	1
2. REPORT SYNOPSIS	3
2.1 Introduction	3
Biomarkers	3
Definitions	3
Therapeutic Areas	3
Oncology	3
Prostate Cancer	3
Ovarian Cancer	4
Breast Cancer	4
Lung Cancer	4
Other Cancer Diseases	4
Liver Cancer	4
Testicular Cancer	4
Thyroid Cancer	4
Colorectal Cancer	5
Pancreatic Cancer	5
Renal Cancer	5
Cardiology	5
Coronary Heart Disease	5
Heart Failure	5
Myocardial Infarction	5
Other Cardiological Diseases	6
Diabetes	6
Cardiac Dysrhythmia	6
Classification of Common Cardiac Arrhythmia	6
Rheumatic Fever	6
Cardiomyopathy	6
Pulmonary Heart Disease	6
Neurology	6
Stroke	7
Brain Tumor	7
Neurodegenerative Disorders	7
Other Neurological Disorders	7
Traumatic Brain Injury	7
CNS Infections	7
Infectious Disease	7
Gastrointestinal Infection	7
Respiratory Tract Infections	8
Other Infections	8
Urogenital Infections	8
Viral Hepatitis	8
Hemorrhagic Fever	8
Zoonosis	8
Arbovirus Infection	8
Antibiotic Resistance	8
Bioterrorism	9
Genetic Disorders	9
Other Therapeutic Areas	9
Autoimmune Disease	9
Endocrinelogical Diseases	9
Hematological Diseases	9
Nutritional Deficiencies	9
Hepatic Diseases	9
Renal Diseases	10
Bone or Musculoskeletal Disorders	10
Biomarker Identification Technologies	10
Imaging	10
Genomics	10
Proteomics	10
Metabolomics	10
Gene Expression Analysis	11
Segmentation of Biomarkers	11
2.2 Segmentation of Biomarkers Market	11
Exhibit 1. Segmentation of Global Biomarkers Market by Therapeutic Area and Identification Technology	11
Exhibit 2. Segmentation by Therapeutic Area for Oncology, Cardiology, Neurology & Infectious Diseases	11
2.3 Global Biomarkers Market	12
Exhibit 3. Biomarkers – Global Market Estimations and Predictions (2005-2020) in US$ Million	12
Exhibit 4. List of Global Major Biomarkers Companies	13
3. MARKET DYNAMICS	16
3.1 Global Market Overview	16
3.2 Global Biomarkers Market	16
Exhibit 5. Biomarkers – Global Market Estimations and Predictions (2005-2020) for North America, Europe, Asia-Pacific and Rest of World in US$ Million	17
Exhibit 6. Biomarkers – Global Market Shares (2010, 2015 & 2020) for North America, Europe, Asia-Pacific and Rest of World	18
3.3 North American Biomarkers Market	19
Exhibit 7. Biomarkers – North American Market Estimations and Predictions (2005-2020) for United States and Canada in US$ Million	19
Exhibit 8. Biomarkers – North American Market Shares (2010, 2015 & 2020) for United States and Canada	20
3.3 (I) United States Biomarkers Market	20
3.3 (II) Canadian Biomarkers Market	20
Exhibit 9. List of North American Biomarkers Companies	21
3.4 European Biomarkers Market	23
Exhibit 10. Biomarkers – European Market Estimations and Predictions (2005-2020) for Germany, UK, Italy, France, Spain, Switzerland, Belgium, Sweden, Russia and Rest of Europe in US$ Million	23
Exhibit 11. Biomarkers – European Market Shares (2010, 2015 & 2020) for Germany, UK, Italy, France, Spain, Switzerland, Belgium, Sweden, Russia and Rest of Europe	24
3.4 (I) German Biomarkers Market	24
3.4 (II) United Kingdom Biomarkers Market	24
3.4 (III) Italian Biomarkers Market	25
3.4 (IV) French Biomarkers Market	25
3.4 (V) Spanish Biomarkers Market	25
3.4 (VI) Swiss Biomarkers Market	25
3.4 (VII) Belgian Biomarkers Market	26
3.4 (VIII) Swedish Biomarkers Market	26
3.4 (IX) Russian Biomarkers Market	26
Exhibit 12. List of European Biomarkers Companies	26
3.5 Asia-Pacific Biomarkers Market	28
Exhibit 13. Biomarkers – Asia-Pacific Market Estimations and Predictions (2005-2020) for Japan, China, India, Australia, South Korea and Asia-Pacific in US$ Million	28
Exhibit 14. Biomarkers – Asia-Pacific Market Shares (2010, 2015 & 2020) for Japan, China, India, Australia, South Korea and Asia-Pacific	29
3.5 (I) Japanese Biomarkers Market	29
3.5 (II) Chinese Biomarkers Market	29
3.5 (III) Indian Biomarkers Market	29
3.5 (IV) Australian Biomarkers Market	30
3.5 (V) South Korean Biomarkers Market	30
Exhibit 15. List of Asia-Pacific Biomarkers Companies	30
3.6 Rest of World Biomarkers Market	31
Exhibit 16. Biomarkers – Rest of World Market Estimations and Predictions (2005-2020) for Israel, South Africa, Brazil and Other Countries in US$ Million	31
Exhibit 17. Biomarkers – Rest of World Market Shares (2010, 2015 & 2020) for Israel, South Africa, Brazil and Other Countries	32
3.6 (I) Israeli Biomarkers Market	32
3.6 (II) South African Biomarkers Market	32
3.6 (III) Brazilian Biomarkers Market	32
Exhibit 18. List of Rest of World Biomarkers Companies	32
3.7 Market Trends	33
What are Pharma Companies looking for in Biomarkers?	33
Biomarkers – An Emerging Trend in Pharma Industry	33
Innovative Biomarker Discovery Methods Aid in Drug Development Stages	33
Biomarkers Becoming Important in Developing Better Drugs	34
Pharma Companies Investing Huge Amounts in Biomarkers Discovery	34
3.8 Company Profiles – Major Players in Biomarkers Market	35
20/20 GeneSystems, Inc. (USA)	35
Abbott Diagnostics (USA)	36
Affymetrix, Inc. (USA)	40
Agendia BV (The Netherlands)	44
Agilent Technologies, Inc. (USA)	46
Alere, Inc. (USA)	47
Almac Group Ltd. (UK)	50
AltheaDx, Inc. (USA)	52
Amarantus BioScience Holdings, Inc. (USA)	53
Asuragen, Inc. (USA)	54
Atherotech (USA)	55
Banyan Biomarkers, Inc. (USA)	58
Beckman Coulter, Inc. (USA)	60
Becton Dickinson and Company (USA)	61
BG Medicine, Inc. (USA)	61
Biacore International AB (Sweden)	62
Biocartis SA (Switzerland)	64
BioChain Institute, Inc. (USA)	65
Biocrates Life Sciences AG (Austria)	67
BioForce Nanosciences, Inc. (USA)	69
BioMarker Pharmaceuticals, Inc. (USA)	70
bioMérieux SA (France)	71
Biophysical Corporation (USA)	73
Bio-Rad Laboratories, Inc. (USA)	74
BioSense Laboratories AS (Norway)	76
BioSystems International Kft. (BSI) (France)	77
bioTheranostics, Inc. (USA)	78
Caprion, Inc. (Canada)	79
Celera Corporation (USA)	81
Charles River Laboratories International, Inc. (USA)	84
CIS Biotech, Inc. (USA)	85
Clarient Diagnostic Services (USA)	86
Compugen Ltd. (Israel)	87
Covance, Inc. (USA)	89
Dako A/S (Denmark)	90
deCODE Genetics (Iceland)	91
DiaGenic ASA (Norway)	92
DiagnoCure, Inc. (Canada)	93
Diaxonhit Group (France)	95
EKF Diagnostics Ltd. (UK)	98
EMD Millipore Corporation (USA)	102
Enzo Life Sciences, Inc. (USA)	105
Epigenomics AG (Germany)	107
Epistem PLC (UK)	109
Exagen Diagnostics, Inc. (USA)	110
Fujirebio Diagnostics, Inc. (USA)	111
Gene Logic, Inc. (USA)	112
Genedata AG (Switzerland)	113
GeneNews Ltd. (Canada)	114
Genomic Health, Inc. (USA)	115
Genoptix Medical Laboratory (USA)	116
Hologic Gen-Probe, Inc. (USA)	118
Health Discovery Corporation (USA)	119
HealthLinx Limited (Australia)	120
Human Metabolome Technologies, Inc. (Japan)	121
IBEX Technologies, Inc. (Canada)	122
Illumina, Inc. (USA)	123
InforSense Ltd. (UK)	124
Insilicos LLC (USA)	125
IntegraGen SA (France)	126
Lee BioSolutions, Inc. (USA)	127
Life Technologies Corporation (USA)	130
Luminex Corporation (USA)	132
Metabolon, Inc. (USA)	135
Minomic International Limited (Australia)	136
Monogram Biosciences, Inc. (USA)	137
Myriad RBM, Inc. (USA)	140
Nonlinear Dynamics Ltd. (UK)	141
Northwest Biotherapeutics, Inc. (USA)	142
Novartis AG (Switzerland)	144
Ocimum Biosolutions Ltd. (India)	144
OPKO Health, Inc. (USA)	146
Orion Genomics (USA)	148
PamGene International BV (The Netherlands)	150
PerkinElmer, Inc. (USA)	151
Phenomenome Discoveries, Inc. (Canada)	153
Pronota NV (Belgium)	155
Proteome Sciences plc (UK)	156
Provista Diagnostics, Inc. (USA)	157
PXBioVisioN GmbH (Germany)	158
Qiagen N.V (The Netherlands)	159
Quest Diagnostics, Inc. (USA)	162
Response Genetics, Inc. (USA)	163
Roche Diagnostics (Switzerland)	165
Shimadzu Scientific Instruments, Inc. (USA)	166
Siemens Healthcare Diagnostics, Inc. (USA)	166
Singulex, Inc. (USA)	168
SoftGenetics LLC (USA)	169
Soiken Holdings, Inc. (Japan)	172
SomaLogic, Inc. (USA)	172
Synexa Life Sciences (South Africa)	173
Thermo Fisher Scientific, Inc. (USA)	174
Thermo Scientific B•R•A•H•M•S Biomarkers (Germany)	175
Transgenomic, Inc. (USA)	178
Tyrian Diagnostics Limited (Australia)	179
Vermillion, Inc. (USA)	180
3.9 Major Activities in Biomarker Industry	182
Thermo Fisher Scientific and Nuclea Biotechnologies Enter into Collaboration	182
Johnson & Johnson Innovation Enters into Collaboration for Immuno-Oncology Lung Cancer with the Belfer Institute for Applied Cancer Science of Dana-Farber Cancer Institute	182
Enterome and Mayo Clinic Enters into Collaboration for the Development and Commercialization of Microbiome-based Diagnostic Tools for Nutritional Interventions	182
Qiagen and Lilly Enter into Collaboration for Joint Development of Companion Diagnostics for Simultaneous Analysis of DNA and RNA Biomarkers in Common Cancers	183
Berg and Medical University of South Carolina Enter into Collaboration for Discovery of Lupus Biomarker	183
Targos Inks a Strategic Biomarker Partnership Agreement with WuXi	183
bioTheranostics Enters into Agreement with National PPO Network Prime Health Services	184
PCLS Inks Agreement with PB to Acquire CertNDx Bladder Cancer Diagnostic Testing Assets	184
bioTheranostics Signs Contract with Three Rivers Provider Network	184
Sony DADC and Singulex Enter into Strategic Partnership for Proprietary Detection Vessels	185
WuXi PharmaTech Joins Hand with Pacific Biomarkers	185
Thermo Fisher Acquires Life Technologies	185
Miraculins Inks a Supply Agreement with Alere to support Endoglin Program	186
R-Biopharm AG Enters into a Strategic Partnership Agreement with CANDOR	186
ApoCell Expands Footprint; Establishes Offices and Laboratories in Germany	186
Agilent Technologies Enters into Partnership with Seoul National University Hospital for Biomarker Research	187
Exosome Diagnostics Enters into Collaboration Agreement with Lilly for Exosome Blood-based Biomarker Discovery	187
Merck Enters into a Strategic Collaboration Agreement with BGI	187
Waters Buys Stake in Nonlinear Dynamics	188
Response Genetics Acquires Pathwork Diagnostics	188
Matrix-Bio Enters into Agreement with Purdue University	188
Eurofins MWG Operon Enters into Co-Marketing Agreement with Floragenex	189
Ventana Medical Systems Collaborates with Translational Genomics Research Institute	189
DaVita Labs and Myriad RBM Enter into Biomarker Research Collaboration	189
GVK Biosciences Licensed its GOSTAR to the US Food and Drug Administration	190
Genome Institute of Singapore Enters into Partnership with Sengenics	190
A* STAR’s Genome Institute of Singapore Enters into Partnership with Oxford Biodynamics	190
PamGene Joins Largest Academia-SME Collaboration Ever	191
Qiagen Enters into Licensing Agreements	191
Luminex Corp., and EMD Millipore Protracts Global Supply and Distribution Agreement	192
Entelos in Association with ISB Announces Successful Gene Expression Breakthrough	192
Qiagen Takes Over Ingenuity Systems	192
PerkinElmer Enters into New Collaboration with the National Center for Drug Screening to Advance Personalized Medicine and Drug Profiling in China	193
AstraZeneca and Karolinska Institutet to Establish New Center for Translational Research	193
Merck Collaborates with Luminex for Development of Companion Diagnostic	194
HTG and Sanofi US Sign Biomarker Collaboration	194
CIGENE Collaborates with Affymetrix on a Salmon Genotyping Array	194
License Agreement for Septin 9 Signed by Epigenomics and BioChain	195
Lab21 Partners with IntegraGen for Colorectal Cancer Diagnostics	195
WaferGen Bio-systems Enters into Co-Marketing Agreement with QIAGEN KK	195
KineMed, Isis Pharmaceuticals and CHDI Foundation Collaborates for Huntington’s Disease Therapeutics and Companion Biomarker Collaboration	196
Qiagen Signs Collaboration Agreement with Eli Lilly	196
Affymetrix and DNA Link Enter into Alliance for Forensic Test Development to Human Identification	196
Institute for Systems Biology Enters into Partnership with AB SCIEX for Predictive and Personalized Heathcare	197
Nordic Immunological Labs Takes Over MUbio	197
Caprion Leads PMPC	197
Qiagen Expands Personalized Healthcare Diagnostics Pipeline	198
GVK Biosciences and Onconova Therapeutics Enter into Partnership to Develop New Drug for Cancer	198
Bio-Rad Labs Acquires AbD Serotec	198
JPT Peptide Technologies and the Institute for Medical Immunology Collaborates on Chronic Fatigue Syndrome	199
Veridex Collaborates with LabCorp to Market CellSearch® CTC Test in China	199
Cancer Stem Cell Agent Companion Diagnostic – An Outcome of Verastem and LabCorp Agreement	199
Ezose Sciences Signs Glycomics Research Agreement with Kyowa Hakko Kirin	200
Mitomics Signs Sales and Marketing Agreement with Sterling Pathology	200
Response Biomedical Enters Distribution Agreement with Laboratory Supply Company (LABSCO)	200
Amorfix Collaborates with QPS for Alzheimer’s Disease Project	201
Myriad Enters into Diabetes Collaboration with Sanofi	201
Metabolon Renews Research Agreement with Syngenta	201
Merck and GE Healthcare Join Hands for Usage of Imaging Biomarkers for Investigational BACE Inhibitor Clinical Development Program	202
Exonhit Acquires InGen BioSciences, a Major In-vitro Diagnostics Distributor in France	202
OGT Inaugurates New York Office	202
biomérieux Enters into Agreement with Quanterix	202
Genedata Collaborates with Life Technologies to Expedite NGS Data Analysis and Real-time PCR-based Validation	203
Thermo Fisher Enters into Licence Agreement with Fujirebio Inc.	203
Affymetrix Enters into Research Partnership with the Center for Proteomic and Genomic Research in South Africa	204
SomaLogic Collaborates with HUNT Biosciences	204
bioMérieux Enters into a Renewed Partnership with Thermo Fisher Scientific	204
Life Technologies Takes Over Compendia Bioscience	204
Ezose Sciences Join Hands with Fast Forward MS Biomarker Discovery	205
Aushon BioSystems and AH diagnostics Enter into Distribution Agreement for Scandinavia	206
Bayer Healthcare and Qiagen Partners to Develop Cancer Companion Diagnostic Tests	206
Entelos Enters into Agreement with the Biomarker Consortium	206
Qiagen Join Hands with China’s Lepu Medical	207
Hologic Acquires Gen-Probe	207
Proteome Sciences Collaborates with CHDI Foundation	207
Metabolon Acquires Lipomics Technologies to Strengthen its Metabolomics Leadership	208
QPS Takes Over JSW Life Sciences	208
Bluechiip and Gentris Corp., Enter into Partnership	208
Agilent Technologies Collaborates with Samsung Medical Center to Work on Clinical Research Projects	209
EKF Diagnostics Enters Licensing Agreement with Joslin Diabetes Center	209
Agilent Technologies Contracts with Gachon University on Discovery of Biomarkers for Cancer and Diabetes	209
Trans Genic Establishes a JV Company with Immuno-Biological Laboratories Co.	210
Agilent Technologies Acquires Danish Cancer Diagnostics Company Dako	210
Merck Serono Ventures and Compugen Ltd., Establishes New Joint Venture Neviah Genomics Ltd., a Biomarker Company	211
Tethys Bioscience Enters Into Strategic Partnership with Lose It! to Curb Diabetes	211
Gentris Corp., Enters into MoU with the Shanghai Institutes of Preventive Medicine	211
Affymetrix Enters into Research Partnership with Massachusetts General Hospital	212
Companion Dx Reference Lab and Epigenomics AG Enter into a Non-Exclusive License Agreement for Septin9	212
XDx Enters into Collaboration and License Agreement with LabCorp	212
Critical Diagnostics Widens Asia-Pacific Footprint	213
GE Healthcare Acquires SeqWright, Inc., to Expand Clarient’s Clinical Diagnostics Offerings	213
Lab21 in Association with ITOR Inaugurates Clinical Genomics Center in the US	213
Almac Enters into WorldWide Distribution Agreement with Affymetrix	214
IO Informatics and Sage-N Research Pool Resources	214
Qiagen Collaborates with Bio-X Center	215
Bristol-Myers Squibb Collaborates with Meso Scale Discovery to Develop Diagnostic Assays for Alzheimer’s Disease	215
Mayo Medical Laboratories Enters into Agreement with A&G Pharmaceutical	215
Selventa and Janssen Research & Development Enter into a Research Agreement	216
Aushon BioSystems Enters into Agreement with Fisher Scientific	216
SQI Diagnostics Signs Agreement with Integrated Sciences	216
Lab21 Enters into Licensing Agreement with Cooperative Diagnostics	216
Quintiles Establishes New Biomarker Research and Development Company	217
Trans-Hit Biomarkers Enters Co-Marketing Agreement with Biomnis	217
Affymetrix Enters into MoU with BGI to Co Produce and Market Genomic Microarrays for the Agricultural Society	217
Sanguine Biosciences and TGA Sciences Join Hands to Strengthen Bioassay Development	218
Ventana Enters into Partnership with Pfizer and CST on Companion Diagnostic	218
Vermillion Acquires Ovarian Cancer Diagnostics Business of Correlogic Systems	218
Pacific Biomarkers and Clinigene International Collaborates to Develop Specialty Biomarker and Provide High-End Clinical Lab Services	219
Lineagen and Fast Forward in Collaboration for Development of Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis	219
Protagen and Bayer HealthCare Expands Collaboration	219
Expedeon Merges with Protein Discovery	219
AB SCIEX Enters into India’s Scientific Community with the Acquisition of MS Business of Labindia	220
GVK Biosciences Collaborates with the PROOF Center of Excellence, University of British Columbia for Biomarkers Development and Commercialization	220
Oncodesign and Taconic Collaborates to Develop and Promote Oncology Research	221
Exonhit and Pfizer in Research Agreement for Identification of Alzheimer’s Disease Biomarkers	221
ACR Image Metrix Collaborates with Radiopharmacies for a Development Program on Imaging Biomarkers	221
Caliper and DxTerity Collaborates to Provide NEAT® Multiplex Assays based upon Caliper’s LabChip® Dx Platform	222
Michael J. Fox Foundation and Kinetics Foundation in Collaboration to Develop Biomarker for Parkinson’s disease	222
Clarient and HistoRx® Agree upon the Usage of AQUA® Technology for Clinical Trials	223
Merck Strategically Collaborates with BGI to Develop Biomarkers and Genomic Technologies	223
Thermo Fisher Acquires Intrinsic Bioprobes	223
SignatureMD Partners with Biophysical Corp., for Promoting Pre-Diabetes Biomarker based Test Across the Country	224
LabCorp Clinical Trials and David H. Murdock Research Institute Strategically Collaborates for Biomarker and Assay Development Services	224
Digilab Signs Agreement with Axela to Market Axela’s Multiplex Biomarker Analysis Platforms in the United States	225
Ariadne and BioMarCare Collaborates to Develop Pharmacogenomic Test Related to Colorectal Cancer	225
Vermillion Enters into Distribution Agreement with Pronto	226
Cell Biosciences Adopts New Corporate Identity ‘ProteinSimple’	226
Proteome Sciences and Buck Institute in Collaboration to Develop Biomarker Tests for Superior Treatment of Breast Cancer	226
Ipsen Collaborates with Institut de cancérologie Gustave Roussy	227
AltheaDx and Gynecologic Oncology Group Teams Up for Enhanced Molecular Testing Services	227
Signal Genetics Signs a USD13.3M Agreement with Diagnocure for Marketing Previstage™ GCC- A Colorectal Cancer Staging Test	227
Myriad Genetics Acquires Rules-Based Medicine	228
Clearstone Central Laboratories Acquired by LabCorp	228
Rosetta Genomics and UC Davis Collaborates for Development and Validation of microRNA Biomarker to Predict Response to Neoadjuvant Chemotherapy in Bladder Cancer	228
Indiana CTSI Enters into Collaboration with GVK Biosciences to Offer Biomarker Database Access throughout US	228
Alere Advances Preeclampsia Program of Miraculins	229
Centocor Ortho Biotech gets Worldwide License to Develop and Market RON-Targeted Antibody Portfolio of AVEO Pharmaceuticals	229
OncoPet Diagnostics Enters into an Agreement with Success Vision Biotek Inc., for the Distribution of RECAF™ Test for Companion Animals	230
AbD Serotec Division Licenses Protemika for 7 Diagnostic HuCAL Anti-bodies	230
HealthLinx Signs Agreement for Prostate Cancer Biomarkers, Ovarian Cancer Dx	230
Exclusive Global License to Transgenomic for PredictiveMarkers in Cancer Drug Response	231
Flagship Biosciences Acquires License from University of Minnesota on Multiplexing Software	231
GVK Biosciences Licenses its GOBIOM Biomarker Database to FDA	232
Quest Diagnostics and Vermillion to Market OVA1® in India	232
SQI Diagnostics Announced Validation Agreement for Vasculitis Test with University of North Carolina Kidney Center	232
HTG Adopts New Corporate Identity- ‘HTG Molecular Diagnostics’	233
Boston Scientific and BG Medicine Sign Contract for Finding Biomarkers Related to Cardiac-Resynchronization and Congestive Heart Failure Treatments	233
Integrated Solutions from Caliper and HistoRx for Better Protein Quantification of Biomarkers in Tissue	233
Caliper Partners with HistoRx for Enhanced Protein Biomarkers Quantification in Tissue	234
Epistem and Sanofi-Aventis in Collaboration	234
MedTrust Online (MedTrust) and Avantra Biosciences (Avantra) Collaborate to Develop Biomarker Assay for Cancer Detection	235
Clinixion Merges with Pharmatest	235
Pronota Collaborates with Molecuence for the Discovery of Protein Biomarkers	235
BG Medicine to Collaborate with Siemens Healthcare for Developing Diagnostic Test based on Galectin-3	236
Atherotech Acquired by a New York based Investment Firm	236
Affymetrix and Fisher Scientific Enter into Distribution Agreement to Expand Market for GeneAtlas™	237
Zinfandel in Global Licensing Agreement with Takeda for TOMM40 Biomarker Assay	237
Expression Pathology Enters into Agreement with Roche for Liquid Tissue®-SRM Protein Biomarker Assay Services	238
RBM and SMA Foundation Come Together for Plasma Protein Biomarkers	238
OSI Pharmaceuticals Exercises its Right to Use AVEO’s Proprietary Platform for Research	239
Metamark Signs Licensing Agreement with HistoRx	239
WaferGen Signs Strategic Agreement with Integrated BioBank of Luxembourg (IBBL)	239
Clinical Data Finalizes Deal with Transgenomic on Biomarker Development	240
LGC Completes the Acquisition of HFL Sport Science	240
MDxHealth Amends Existing Agreement for Methylation Biomarker with Veridex	241
Clinical Data Concludes Sale of FAMILION® Testing and Pharmacogenomics Biomarker Development Business to Transgenomic	241
Caliper Acquires Cambridge Research & Instrumentation (CRI)	242
Flagship Enters into Partnership with Expression Pathology	242
EKF Diagnostics Acquires Argutus Medical	242
Pfizer and DiaGenic Enter into Partnership for the Development of Blood based Biomarkers	243
U.S. Genomics Changes Corporate Identity to Pathogenetix	243
Aushon BioSystems in Association with LightArray Biotech Provides Multiplex Biomarker Products and Services in China	243
PRECOS in Multi Year Global Service Agreement with Janssen	244
BioMérieux Enters into Partnership Agreement with Biocartis	244
Dako to Distribute Bioporto’s NGAL Test	245
GSTP1 Licensing Agreement Extended by Predictive Biosciences and Epigenomics	245
ICON plc and Proteome Collaborate for Expanded Biomarker Solutions	245
Oryzon Signs Non-Exclusive License Agreement with Dyax Corp.	246
Predictive Biosciences Obtains License to Biomarkers for Bladder Cancer from MDxHealth	246
diaDexus Announces Change of Name from VaxGen	246
Quintiles Collaborates with London Genetics to Use Pharmacogenetics for the Discovery and Development of Novel Drugs	246
Active Motif Takes Over Genpathway Inc.,	247
Genstruct Inc., Adopts New Corporate Identity	247
London Genetics and Astrimmune Forms Collaboration for Cancer Vaccine	248
PPD and VirtualScopics Strategically Ally with for Medical Imaging Services	248
PBS-Bio Enters into Collaboration to Accelerate Development of Cancer Drug	248
OncoMethylome Sciences Renamed to MDxHealth	249
Gentel and RayBiotech Collaborates for a Comprehensive Selection of Arrays	249
Evotec Enters into Drug Discovery Alliance with Shionogi	250
Protagen AG Joins Hands with MicroDiscovery GmbH for Biomarker Development	250
Sanofi-Aventis Enters into Collaboration Agreement with Belfer Institute	250
Ariana Pharma in Collaboration with FDA for the Development of Biomarkers	251
Fujirebio Acquires Innogenetics	251
London Genetics and Diaceutics in Development Collaboration for Biomarker Research Software Decision Tools	251
Proteome Enters into Collaboration with Thermo Fisher for Protein Biomarkers	251
Proteomics to Commercialize Discovery and Validation of 13 Diabetes Biomarkers	252
Ariadne Collaborates with BIO-NMD Consortium to Locate Biomarkers	252
Genesis Genomics Renames to Mitomics	252
Formation of Bertin Pharma	253
Medical College of Georgia Spins off, a Novel Biomarker Company	253
PROOF Center and CINS Jointly Fights Against Cardiovascular Disease	253
TcLand Expression Enters into Strategic Partnership for Development of Novel RA Biomarkers	253
Stemina Biomarker and Pioneer Hi-Bred Sign Research Agreement	254
Astellas Pharma Completes Acquisition of OSI Pharmaceuticals	254
OriGene and ISB Alliance for SRM/MRM Database	255
Genetic Technologies Acquires the Assets of Perlegen	255
Duke Associates with LabCorp to Develop a Joint Venture Company, the Biomarker Factory…	255
Thermo Fisher Enters into a Collaboration Agreement with LCP for Improved Biomarker Discovery and Assay Development Process…	256
Axela Associates with Salomao & Zoppi and CRIA Opportunities	256
SQI Diagnostics Enters into a Development Deal with Silliker for Marketing of Botulism Toxin Panel…	256
PROOF Center Enters into Partnership Agreement with Luminex	257
Celerion Completes Acquisition of MDS Pharma Services' Early Stage Clinical Development Operations	257
Philips Signs an MoU with Definiens for Co-Developing and Marketing Solutions for Digital Pathology	258
Ricerca Biosciences LLC Buys MDS Pharma Services	258
PAREXEL International and Proteome Sciences Forms an Alliance for Biomarker Development	259
Biocartis Acquires Automated DNA/RNA Molecular Diagnostic Testing Platform of Philips	259
AB SCIEX Acquires Eksigent Liquid Chromatography Business	260
Change of Corporate Name of Pacific Biometrics Inc., to Pacific Biomarkers Inc	260
Agreement between MDxHealth, Pfizer, Cancer Research Technology (CRT) and Newcastle University (UK) for Predictive Biomarker Identification for PARP Inhibitor Therapies	260
Bio-Rad Acquires Specified Diagnostics Businesses of Biotest AG	261
Caprion Proteomics Buys Biomarker Division of PPD	261
VisEn Gains Prominent Fluorescence Agent Intellectual Property Portfolio and Technology Platforms from Bayer Schering Pharma	261
Philips and bioMérieux Enter into Partnership for the Development and Marketing POC Solutions	262
AdnaGen AG Enters into Agreement with TATAA Molecular Diagnostics	262
Wuxi AppTec and QIAGEN Enter into Biomarker Development Partnership	263
Acquisition of ACE Biosciences by Zymenex	263
eBioscience Completes the Acquisition of Bender Medsystems	264
Agilent Technologies Declares the Opening of Shanghai Institute of Biological Sciences, a Center for Systems Biology	264
Beckman Coulter Completes formation of Beckman Coulter Genomics	264
ICON Takes Over Veeda Laboratories	264
SiDMAP Forays into Japanese Market	265
Collaboration between Agilent Technologies and Anderson Forschung Group on Quantitative Protein Assays	265
BD and Fujirebio Diagnostics Sign Worldwide Agreement for Development of Biomarker Assays	265
Clinical Data Takes Over Avalon Pharmaceuticals	266
Clinical Data Enters into a Deal on Cogenics Sale with Beckman Coulter	266
Celera Enters into License Agreement with Perlegen and deCODE	266
Gen‐Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3‐Based Prostate Cancer Tests	267
Aushon BioSystems Completely Acquires Thermo Fisher’s SearchLight Business and Technology	267
Sense Proteomic Acquired by Oxford Gene Technology (OGT)	268
Cordex Pharma Joins Hands with BG Medicine to Undertake Clinical Trial of Heart Failure Biomarkers	268
Gene Logic Enters into Agreement with Genstruct	268
Sequenom Takes Over SensiGen’s Molecular Diagnostics	269
Sysmex Europe Gmbh Enters into Agreement with AdnaGen to Distribute Products for the Detection of Circulating Tumor Cells	269
Genedata and Syngenta Extend Biomarker Discovery Collaboration	270
Thermo Fisher Scientific Acquires B•R•A•H•M•S	270
Sigma-Aldrich Acquires Seppro® Depletion Technology from GenWay Biotech	270
Rubicon and Abbott in Licensing Agreement for Development and Commercialization of DNA Methylation Cancer Tests	271
XDx and Bristol-Myers Squibb in Pharmacogenomics Collaboration	271
WaferGen and University of Texas Southwestern Medical Center in collaboration for Biomarker Research for SmartChip™ Real-Time PCR System	271
GCIC Grants $550,000 to Prognostix to Assist Product Development & Commercialization	272
3.10 Major Product Innovations/Launches in Biomarker Industry	273
Amgen to Assist National Cancer Institute and Its Research Partners to Develop Personalized Treatment Approaches for Squamous Cell Lung Cancer	273
Merck Alliances with Sysmex Inostics to Develop and Supply a Blood-based RAS Biomarker Test	273
Clinigene Launches Best-in-class Biomarker Assay to Evaluate ABCA1 Specific Cholesterol Efflux	273
NanoString Technologies Collaborates with Celgene Corporation	273
Pioneering Clinical Trial Launched	274
Aushon Receives Three New Patents	274
Fujirebio Europe Unveils LUMIPULSE® G ProGRP	275
QIAGEN Expands Personalized Healthcare Assay Pipeline through Addition of a Promising New Biomarker for Superior Diagnosis of Blood Disorders	275
Galectin-3 Now included in 2014 Indian Consensus Document on Cardiac Biomarkers	275
BioAgilytix is the First CRO to Authenticate Meso Scale Discovery’s V-PLEX Human Cytokine 30-Plex Assay	275
SomaLogic Receives Additional Funding to Develop TB Diagnostic Test	276
Clinical Study by Berg and the Parkinson's Institute and Clinical Center on Game-changing Innovations in Parkinson's disease Biomarker Discovery	276
bioTheranostics Introduces bioT3 Metastatic Cancer Solution	277
Fujirebio Europe Advances Range of Immunoassay Biomarkers for Alzheimer Routine Testing	277
QIAGEN and Exosome Diagnostics Expands Collaboration for the Development of Non-Invasive Biofluid Diagnostic for Lung Cancer	277
Selventa Obtains Patent to Extract Knowledge from Biological Networks	278
US FDA Grants 510(k) Approval to Affymetrix’s CytoScan® Dx Assay	278
ACS Biomarker Advances Biomarker Validation in Large Scale Heart Failure Patient Cohorts	278
Quintiles to Accelerate Biomarker-Targeted Therapies for Cancer Patients through Innovative Approach	279
Mount Sinai and Exosome Diagnostics Enter into Collaboration to Accelerate Translation of Body Fluid Molecular Diagnostics	279
Atherotech Diagnostic Lab Releases Lipid Panel VAP®+	280
Plexera Launches Lectin Array Chip	280
Miraculins Acquires the SCOUT DS®	280
Critical Diagnostics’ Biomarker ST2 Now Included in the 2013 ACC/AHA Guidelines for the Management of Heart Failure	281
Integromics Forges Alliance with CITRE and CEIT to Develop New Processes for Drug Discovery Research	281
Critical Diagnostics Expands Global Presence	281
Seegene and Selventa Join Forces	282
Olink Bioscience Launches Scalable Protein Biomarker Assays with Proseek® Multiplex	282
New Collaboration for Indentification of Parkinson’s Disease Biomarkers	282
Agilent Technologies Join Hands with Applied Proteomics	283
Covance Enters into Alliance with M2Gen® to Promote Faster Patient Recruitment in Biomarker-Driven Oncology Trials	283
Quest Diagnostics/Berkeley HeartLab Enters into Agreement with LabCorp to Offer Presage® ST2 Assay for Heart Failure	283
Biocartis Commercially Launches New Biomarker Analysis Platform	284
Fast Forward and DioGenix Collaborates to Speed up MS Diagnosis and Monitoring	284
Northwest Biotherapeutics Collaborates with Leading UK Cancer Institutions for Clinical Trial of DCVax®-Direct	285
Romer Labs Buys Food Safety and GMO Businesses from SDIX for US$ 13.5 Million	285
BG Medicine and Kindstar Diagnostics Enter into Collaboration to Provide Galectin-3 Testing Services in China	286
BD and Lab21 Enter into Collaboration for Development of New Oncology Assays on the BD MAX™ Platform	286
Agilent Technologies Enters into Co-Marketing Agreement with MRM Proteomics	287
GeneNews Enters into Alliance with Shanghai Biochip	287
Critical Diagnostics Partners with Asian Distributors	287
PROOF Center of Excellence Collaborates with OriGene Technologies on Heart & Kidney Transplant Biomarker Program	288
Bio-Rad Collaborates with Myriad RBM for Biomarker Kit Commercialization	288
Expression Analysis Receives US$27 Million Contract from EPA	288
Argutus Medical in Association with ALPCO Launches New Biomarker	289
Fluxion Biosciences Collaborates with Rubicon Genomics	289
HTG Molecular Diagnostics Join Hands with John Wayne Cancer Institute to Market Melanoma Signatures	289
Berg Pharma and the Parkinson’s Institute Enter into R&D Collaboration	290
Aushon Introduces Cira Multiplex Protein Biomarker Platform	290
Genedata and Roche Extends Collaboration of Biomarker Discovery for Personalized Healthcare	290
Ventyx Wesley Research Institute Tissue Bank Joins the BioServe Network	291
Genomic Health Announces Strategic Alliance with OncoMed	291
Abbott’s Novel Biomarkers for Application in Prostate Cancer Type Detection	291
Spinal Muscular Atrophy Foundation Launches Biomarker Panel to Guide SMA Therapeutic Development	292
Takeda and Metabolon Enter into Research Collaboration to Discover New Targets and Biomarkers	292
Ezose Sciences Collaborates with Hirosaki University for Cancer Biomarker Discovery	292
Quintiles Takes Over Expression Analysis	293
Affymetrix Signs World-Wide Distribution Contract with Almac	293
Epistem in Collaboration with Glaxosmithkline for Three Years in Fibrosis Research	294
OGT Enters into Licensing Agreement for Colorectal Cancer Biomarkers	294
Avesthagen and KUTLO-NITT Sign MOU to Develop and Commercialize New Technologies for Healthcare	294
Agilent Technologies Enters Into Collaboration with Integrated Diagnostics	295
Qiagen Collaborates with Max Planck Institute for Infection Biology	295
Ventana Join Hands with Bayer on Companion Diagnostic Test	295
PPD and VirtualScopics Expands Strategic Alliance for Medical Imaging Services to Facilitate Rapid, More Certain Decisions about Compounds	296
Merck Millipore and Proteomics International Collaborate for Validation of Biomarkers of Diabetic Nephropathy	296
€2.3 Million Additional Grant from BMBF to Apogenix	296
NextGen Sciences Receives Patent for Multiple Biomarker Assay	296
New Risk-Benefit-Sharing Business Model Introduced by Trans-Hit Biomarkers for Collaboration between Bio-banks and Biomarker Scientists	297
Notice Allowance to Vermillion for Patent on its Fifth Biomarker for Peripheral Artery Disease	297
Innogenetics Introduces Lumipulse® G1200 — A Fully Automated Chemiluminescent Enzyme Immunoassay System	297
iPLEX® ADME PGx is a New Panel from Sequenom for MassARRAY® System	298
New York State Laboratory Permits Use of Tethys’ PreDx® Diabetes Risk Score	298
Vermillion Receives Patent for Lung Cancer	299
Health Discovery Receive Patent for Screening Prostate Cancer	299
AB SCIEX Releases New Eksigent Chip Column Family for Nano and Micro LC Proteomics Analysis	299
Fujirebio Diagnostics attains FDA approval to market ROMA™	299
Promega Releases ONE-Glo + Tox to Study Gene Expression and Cell Viability	300
New Multiplex Protein CSF Biomarker Assay by NextGen for Alzheimer’s Disease	300
HTG Molecular Diagnostics Launches Whole Transcriptome Array (WTA)	300
US Patent for Cardiovascular Disease Marker Company for ST2 Biomarker in Clinical Testing	301
Champions Biotechnology Adopts New Corporate Identity	301
Emory University and Banyan Biomarkers to Collectively Identify Brain Biomarkers for Phase III Studies on Traumatic Brain Injuries	301
HTG Molecular Diagnostics Launches New Version of MicroRNA Screening Product	302
CE IVD Mark to Caliper’s LabChip® DX	302
Orion Genomics Receives US Patent for Developing an Epigenetic Biomarker for Diagnosing Cancer	303
Thermo Scientific Launches B • R • A • H • M • S TRAK human KRYPTOR	303
CE Mark to VeraLight for SCOUT DS® - A Non-Invasive Diabetes Screening Device	303
Thermo Fisher Scientific Makes Available Biomarker Assays upon Alere Triage Systems	304
Advion BioServices Leads in SISCAPA Assay Services for Biomarker Assays Offering	304
Biomedical Researchers Designed a Novel Approach with AB SCIEX QTRAP Technology for the Quantification of Protein	304
US Patent to Predictive Biosciences for Multiple Biomarker Assay	305
Avantra Biosciences Launches Rapid Assay Prototyping Service based on Biomarkers	305
US Patent to DiagnoCure for PCA3 Prostate Cancer Biomarker	305
NextGen Sciences Launches Multiple Protein Cerebrospinal Fluid CNS Disease Biomarker Assay	306
US Patent to Avesthagen Awarded for an Alternative to Antibiotic Marker Technology in GM Crops	306
Affymetrix Expands the Expression Power of GeneAtlas® Personal Microarray System	307
FUJIREBIO Attains FDA 510 (k) Clearance for First Biomarker to Monitor Lung Cancer	307
Rules-Based Medicine Along with Roche Develops a Landmark in Companion Diagnostic Program	307
FNIH Introduces Trial to Enhance Diagnostic Tools for Diabetes	308
Thomson Reuters Grants Access to Validated Biomarker Data to Advance the Metacore Solution	308
BIOCRATES Life Sciences AG Launches SteroIDQ® Kit by BIOCRATES - An Advanced Device for the Analysis of Steroid Hormones	308
NextGen Sciences Launches Multiplex Protein Plasma Biomarker Assay for Breast Cancer	309
SCOUT DS® of VeraLight for Non-invasive Diabetes Screening Granted Medical Device License by Health Canada	309
Innovative Health Solutions through New Blood Tests to Combat Global Burden of COPD	309
Health Canada Medical Device License to SQI Diagnostics for Multiplexed, Quantitative IgX PLEX Celiac Panel	310
Rules-Based Medicine Releases OncologyMAP® for Cancer Diagnostics	310
Expression Pathology Receives US Patent for Proteomic Analysis of Tissues	311
Gentel Biosciences and Van Andel Institute Release New Detection Technology for Enhancing the Early Cancer Detection and Prognosis	311
Rubicon Genomics Receives Patent for Sample Preparation for Next-Generation Sequencing	311
Cytocell Develops New FGFR1 Probe	312
PLA based Plasma Protein Biomarker-Discovery Service from Olink	312
UNIarray® Platform to be Applied for Biogen Idec by Protagen	313
High-Throughput SmartChip Human MicroRNA Panel from WaferGen	313
AclarusDx™ of ExonHit Awarded CE Mark	314
New Plasma Biomarker Discovery Service from Olink Bioscience	314
Almac Launches CLIA Laboratory for Biomarker Clinical Trials	314
Biomoda Seeks New Patent for its Technology that Increases Effectiveness of CyPath® Assay	314
Expression Analysis to Study Kinase Mutations Associated with Cancer	315
TcLand Expression Initiates a Worldwide Clinical Trial "PRINT" for the Validation of Blood Biomarker RA-INF-Dx	315
Abnova Launches New Complementary FISH Probes to Immuno-HistoChemistry Antibodies	315
Cresset Group Launches FIELDSCREEN 2.6.0	316
Asuragen Receives USPTO Allowance for Diagnostic Applications of Cancer related miRNAs	316
Abbott Receives CE Mark for Vitamin D Test Using ARCHITECT 25-OH Vitamin D Assay	316
Onko Sure® IVD Cancer Test of Radient Pharmaceuticals Awarded CE Certification	316
Illumina Unveils Next Generation of iSelect® Custom Genotyping	317
Avantra Launches Novel Q400 Biomarker workstation and Angio Qx Biochip Immunoassay	317
Celera Files Dossier for the U.S Regulatory Approval of KIFG Genotyping Assay	318
CE Mark to Critical Diagnostics’ Presage® ST2 Assay	318
Vermillion Granted US Patent for PAD Biomarker	319
Abnova Corporation and GSP Laboratory Launch Novel FISH Probes	319
FDA Approves Galectine -3 Test	319
OvPlex of HealthLinx Provides Superior Performance over CA125 in part 1 of Multinational Ovarian Cancer Biomarker Study	320
Cell Biosciences Receives US Patent	320
Exiqon Launches GLP Compliant Services for miRNA Biomarker Screening	321
Merck Millipore Expands its Contract Service Offering by Adopting Gyros Platform	321
USD 244,000 Grant to Pacific Biomarkers for Health Care Reform Initiative	322
Crescendo Bioscience Unveils Multi-Biomarker Blood Test for RA Patients	322
SureGene Obtains SBIR Matching Grant for Genetic Biomarker Technology	322
Ray of Hope for Stomach Cancer Patients as Diagnostic Tests Earn FDA Approval	322
NCI Grants US$ 3 Million to 20/20 GeneSystems for Development of Personalized Medicine Tests	323
New GeneMarker Software Version Released by SoftGenetics	323
Caprion Proteomics Identifies Potential Biomarkers for Prediction of Response to Hepatitis C Treatment	324
Flagship Biosciences Launches New Multiplex Tissue Biomarker Service	324
GeneGo Inc., MetaCore and MetaDrug Software Programs Integrated with Sequence Data Management (SDM) platform	325
20/20 Launches Novel Multiplex Tissue Biomarker Technology	326
Agilent Technologies Launches SureSelect Kinome - Target Enrichment System	326
USD 1.2 Million Grant to A&G Pharmaceutical from Phase II SBIR for Development of Treatment for Breast Cancer	326
Roche Diagnostics Launches STAT Immunoassays for Application in Cardiac Biomarker Testing	327
Almac Introduces Range of New Biomarkers Solutions for Biopharma Industry	327
Agendia Inaugrates New Advanced Genomics Laboratory in Irvine	328
Definiens Launches Tissue Studio 2.0	328
Two Innovative Proteomic Biomarker Assays for Alzheimer’s Disease Developed by Proteome Sciences	329
MJFF Provides US$1.1 Million for Biomarker Candidates Development Projects for Parkinson’s disease	329
Aushon BioSystems Launches Latest Human Multiplex Biomarker Panels	329
WaferGen Biosystems Supplies SmartChip Real-Time PCR System to Kyoto University for Enhancing the Research on Regenerative Tissue…	330
C-Path Becomes First Ever Biomarker Panel to be Approved by Japanese Regulators	330
Tethys Inc., Receives US Patent for the Outstanding PreDx™ Diabetes Risk Score Test	331
Millipore Launches Test Kits for Human Kidney Damage	331
TGen Piloted Group Led Studies Identify Genetic Links to Kidney Disease	332
WaferGen Biosystems Inc., Markets Two of Gene Expression Profiling Panels Designed for SmartChip Real-Time PCR System	332
Cancer Prevention and Research Institute of Texas Awards Funds to Rules-Based Medicine	332
Quintiles Launches Wide-Ranging Suite of PI3K Biomarker Assays	333
BioMarker Strategies Obtains Funds of US$1 Million from NCI	333
StemTroniX and Power3 Submit Patent Application for Stem Cell Protein Biomarkers	334
Pronota Achieves Base of Next Generation Sequencing Application for Identification and Quantification of Proteins	334
bioMérieux and GlaxoSmithKline Enter into Alliance for the Development of Molecular Theranostic Test	334
Compugen Discovers Drug Target to Treat Multiple Myeloma	335
HistoRx Receives Patent on Application of AQUA® Technology	335
Genedata Launches Expressionist 6	335
AB Sciex Introduces TripleTOF™ 5600 System	336
Aushon BioSystems Launches Multiplex Biomarker Panels	336
WaferGen Introduces SmartChip Multi-Sample Dispenser for Cost-Effective Biomarker Validation Employing Gene Expression and Genotyping	336
CRi’s Multispectral Imaging and Analysis Systems used for Biomarker Analysis Using Skin Biopsies	337
Almac Enters into a Joint Venture Agreement with Merck KGaA and the Medical Research Council (MRC)	337
Ocimum Biosolutions Initiates qRT-PCR Services in India	338
Somalogic Employs Aptamers for Better Biomarker Research Tools	338
BforSMA Study Yields 400 Candidate Biomarkers	338
PCA3 Biomarker Helps in Predicting Risk of Aggressive Cancer	339
AB Sciex Launches First Mass Spectrometry based Application for Lipidomics	339
Vermillion and Quest Diagnostics Launches OVA1, an Ovarian Cancer Test	339
US FDA Accepts Abbott’s Biomarker Test for Review	340
USPTO Grants Two New Patents to Metabolon	340
GeneNews Limited Receives another U.S patent for The Flagship Sentinel Principle® Technology	340
BioCurex Commercializes OncoPet RECAF™	341
Targacept Inc., Receives Finances from the Michael J. Fox Foundation for Undertaking Biomarker Research for Parkinson's Disease	341
Shimadzu, Ceres Nanosciences and Nonlinear Dynamics Launches Nanotrap™ Biomarker Discovery Platform	341
Rosetta Genomics and NYU Langone Medical Center Identify Single microRNA Biomarker for Prognosis of Mesothelioma Patients	342
FlowCytomix™ Growth Factor Simplex Kits for Multiple Analyte Detection are Available at Bender MedSystems	342
NextGen Sciences Enters into Agreement to Develop and Validate Protein Biomarker Assays for Takeda Pharmaceuticals	343
Axis-Shield Teams Up with Bio-Rad to Unveil Novel Anti-CCP Test for Bio-Rad’s BioPlex 2200 System	343
Norgen Biotek Corp., Launches New Robust Urine DNA, RNA, micro-RNA, Proteins, Exfoliated Cells and Microorganism Isolation Kits	343
IWT Grants Euro 1.4 Million to Pronota for Validation and Development of Innovative Cardiovascular Biomarkers	344
Abbott Gene-Based Test Receives CE Mark for Colorectal Cancer	344
VisEn Launches Novel Cat B 680 FAST™ Fluorescence Molecular Imaging Agent for Monitoring and Measuring Cathepsin B Activity	344
Patent Awarded to Metabolon for Metabolomics Method	344
Framingham Heart Study (FHS) of NHLBI, Boston University Undertakes a 5-Year CRADA Project with BG Medicine	345
bioMérieux Inks an Theranostics Agreement with GSK for Developing Predictive Test	345
bioTheranostics Signs Contract with Lab21 for Promoting THEROS CancerTYPE ID® Molecular Cancer Classifier in the UK, Ireland and Middle East	346
IPIT Adopts Affymetrix DMET Plus Biomarker to Expand the PGENI	346
M.D. Anderson & Aureon Laboratories Evaluate Biomarkers with Non-Small Cell Lung Cancer	347
AltheaDx Accredited with CLIA Certification	347
Bio-Rad Introduces Bio-Plex Pro Magnetic Bead-Based Human and Mouse Cytokine Assays	347
AdnaGen AG and Onco Vista Therapies Receive Key Patent	348
3.11 Therapeutic Area Analysis	349
Exhibit 19. Biomarkers by Therapeutic Area – Global Market Estimations and Predictions (2005-2020) in US$ Million for Oncology, Cardiology, Neurology, Infectious Disease, Genetic Disorders & Other	349
Exhibit 20. Biomarkers – Global Market Shares (2010, 2015 & 2020) for Oncology, Cardiology, Neurology, Infectious Disease, Genetic Disorders & Other	350
3.11.1 ONCOLOGY	351
3.11.1.1 Global Oncology Biomarkers Market	351
Exhibit 21. Biomarkers in Oncology – Global Market Estimations and Predictions (2005-2020) in US$ Million for Prostate Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer and Other	352
Exhibit 22. Biomarkers in Oncology – Global Market Shares (2010, 2015 & 2020) for Prostate Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer and Other	353
Exhibit 23. Biomarkers in Oncology – Global Market Estimations and Predictions (2005-2020) in US$ Million for North America, Europe, Asia-Pacific and Rest of World	354
Exhibit 24. Biomarkers in Oncology – Global Market Shares (2010, 2015 & 2020) for North America, Europe, Asia-Pacific and Rest of World	355
Exhibit 25. List of Global Oncology Biomarkers Companies	355
3.11.1.2 North American Oncology Biomarkers Market	357
Exhibit 26. Biomarkers in Oncology – North American Market Estimations and Predictions (2005-2020) in US$ Million for USA and Canada	357
Exhibit 27. Biomarkers in Oncology – North American Market Shares (2010, 2015 & 2020) for USA and Canada	358
3.11.1.2 (I) United States Oncology Biomarkers Market	358
3.11.1.2 (II) Canadian Oncology Biomarkers Market	358
3.11.1.3 European Oncology Biomarkers Market	359
Exhibit 28. Biomarkers in Oncology – European Market Estimations and Predictions (2005-2020) in US$ Million for Germany, UK, Italy, France, Spain, Switzerland, Belgium, Sweden, Russia and Rest of Europe	359
Exhibit 29. Biomarkers in Oncology – European Market Shares (2010, 2015 & 2020) for Germany, UK, Italy, France, Spain, Switzerland, Belgium, Sweden, Russia and Rest of Europe	360
3.11.1.3 (I) German Oncology Biomarkers Market	360
3.11.1.3 (II) United Kingdom Oncology Biomarkers Market	360
3.11.1.3 (III) Italian Oncology Biomarkers Market	360
3.11.1.3 (IV) French Oncology Biomarkers Market	360
3.11.1.3 (V) Spanish Oncology Biomarkers Market	361
3.11.1.3 (VI) Swiss Oncology Biomarkers Market	361
3.11.1.3 (VII) Belgian Oncology Biomarkers Market	361
3.11.1.3 (VIII) Swedish Oncology Biomarkers Market	361
3.11.1.3 (IX) Russian Oncology Biomarkers Market	361
3.11.1.4 Asia-Pacific Oncology Biomarkers Market	362
Exhibit 30. Biomarkers in Oncology – Asia-Pacific Market Estimations and Predictions (2005-2020) in US$ Million for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific	362
Exhibit 31. Biomarkers in Oncology– Asia-Pacific Market Shares (2010, 2015 & 2020) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific	363
3.11.1.4 (I) Japanese Oncology Biomarkers Market	363
3.11.1.4 (II) Chinese Oncology Biomarkers Market	363
3.11.1.4 (III) Indian Oncology Biomarkers Market	363
3.11.1.4 (IV) Australian Oncology Biomarkers Market	363
3.11.1.4 (V) South Korean Oncology Biomarkers Market	363
3.11.1.5 Rest of World Oncology Biomarkers Market	364
Exhibit 32. Biomarkers in Oncology – Rest of World Market Estimations and Predictions (2005-2020) in US$ Million for Israel, South Africa, Brazil and Other Countries	364
Exhibit 33. Biomarkers in Oncology – Rest of World Market Shares (2010, 2015 & 2020) for Israel, South Africa, Brazil and Other Countries	365
3.11.1.5 (I) Israeli Oncology Biomarkers Market	365
3.11.1.5 (II) South African Oncology Biomarkers Market	365
3.11.1.5 (III) Brazilian Oncology Biomarkers Market	365
3.11.1. A PROSTATE CANCER	366
3.11.1. A .1 Global Prostate Cancer Biomarkers Market	366
Exhibit 34. Prostate Cancer Biomarkers – Global Market Estimations and Predictions (2005-2020) in US$ Million for North America, Europe, Asia-Pacific and Rest of World	366
Exhibit 35. Prostate Cancer Biomarkers – Global Market Shares (2010, 2015 & 2020) for North America, Europe, Asia-Pacific and Rest of World	367
3.11.1.A .2 North American Prostate Cancer Biomarkers Market	368
Exhibit 36. Prostate Cancer Biomarkers– North American Market Estimations and Predictions (2005-2020) in US$ Million for USA and Canada	368
Exhibit 37. Prostate Cancer Biomarkers – North American Market Shares (2010, 2015 & 2020) for USA and Canada	369
3.11.1. A .2 (I) United States Prostate Cancer Biomarkers Market	369
3.11.1.A .2 (II) Canadian Prostate Cancer Biomarkers Market	369
3.11.1.A .3 European Prostate Cancer Biomarkers Market	370
Exhibit 38. Prostate Cancer Biomarkers– European Market Estimations and Predictions (2005-2020) in US$ Million for Germany, UK, Italy, France, Spain, Switzerland, Belgium, Sweden, Russia and Rest of Europe	370
Exhibit 39. Prostate Cancer Biomarkers – European Market Shares (2010, 2015 & 2020) for Germany, UK, Italy, France, Spain, Switzerland, Belgium, Sweden, Russia and Rest of Europe	371
3.11.1.A .3 (I) German Prostate Cancer Biomarkers Market	371
3.11.1.A .3 (II) United Kingdom Prostate Cancer Biomarkers Market	371
3.11.1.A .3 (III) Italian Prostate Cancer Biomarkers Market	371
3.11.1.A .3 (IV) French Prostate Cancer Biomarkers Market	371
3.11.1.A .3 (V) Spanish Prostate Cancer Biomarkers Market	372
3.11.1.A .3 (VI) Swiss Prostate Cancer Biomarkers Market	372
3.11.1.A .3 (VII) Belgian Prostate Cancer Biomarkers Market	372
3.11.1.A .3 (VIII) Swedish Prostate Cancer Biomarkers Market	372
3.11.1.A .3 (IX) Russian Prostate Cancer Biomarkers Market	372
3.11.1.A .4 Asia-Pacific Prostate Cancer Biomarkers Market	373
Exhibit 40. Prostate Cancer Biomarkers – Asia-Pacific Market Estimations and Predictions (2005-2020) in US$ Million for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific	373
Exhibit 41. Prostate Cancer Biomarkers – Asia-Pacific Market Shares (2010, 2015 & 2020) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific	374
3.11.1.A .4 (I) Japanese Prostate Cancer Biomarkers Market	374
3.11.1.A .4 (II) Chinese Prostate Cancer Biomarkers Market	374
3.11.1.A .4 (III) Indian Prostate Cancer Biomarkers Market	374
3.11.1.A .4 (IV) Australian Prostate Cancer Biomarkers Market	374
3.11.1.A .4 (V) South Korean Prostate Cancer Biomarkers Market	374
3.11.1.A .5 Rest of World Prostate Cancer Biomarkers Market	375
Exhibit 42. Prostate Cancer Biomarkers – Rest of World Market Estimations and Predictions (2005-2020) in US$ Million for Israel, South Africa, Brazil and Other Countries	375
Exhibit 43. Prostate Cancer Biomarkers – Rest of World Market Shares (2010, 2015 & 2020) for Israel, South Africa, Brazil and Other Countries	376
3.11.1. A .5 (I) Israeli Prostate Cancer Biomarkers Market	376
3.11.1.A .5 (II) South African Prostate Cancer Biomarkers Market	376
3.11.1.A .5 (III) Brazilian Prostate Cancer Biomarkers Market	376
3.11.1. B OVARIAN CANCER	377
3.11.1. B .1 Global Ovarian Cancer Biomarkers Market	377
Exhibit 44. Ovarian Cancer Biomarkers – Rest of World Market Estimations and Predictions (2005-2020) in US$ Million for North America, Europe, Asia-Pacific, Rest of World	377
Exhibit 45. Ovarian Cancer Biomarkers – Rest of World Market Shares (2010, 2015 & 2020) for North America, Europe, Asia-Pacific, Rest of World	378
3.11.1. B .2 North American Ovarian Cancer Biomarkers Market	379
Exhibit 46. Ovarian Cancer Biomarkers– North American Market Estimations and Predictions (2005-2020) in US$ Million for USA and Canada	379
Exhibit 47. Ovarian Cancer Biomarkers – North American Market Shares (2010, 2015 & 2020) for USA and Canada	380
3.11.1. B .2 (I) United States Ovarian Cancer Biomarkers Market	380
3.11.1. B .2 (II) Canadian Ovarian Cancer Biomarkers Market	380
3.11.1. B .3 European Ovarian Cancer Biomarkers Market	381
Exhibit 48. Ovarian Cancer Biomarkers– European Market Estimations and Predictions (2005-2020) in US$ Million for Germany, UK, Italy, France, Spain, Switzerland, Belgium, Sweden, Russia and Rest of Europe	381
Exhibit 49. Ovarian Cancer Biomarkers – European Market Shares (2010, 2015 & 2020) for Germany, UK, Italy, France, Spain, Switzerland, Belgium, Sweden, Russia and Rest of Europe	382
3.11.1. B .3 (I) German Ovarian Cancer Biomarkers Market	382
3.11.1. B .3 (II) United Kingdom Ovarian Cancer Biomarkers Market	382
3.11.1. B .3 (III) Italian Ovarian Cancer Biomarkers Market	382
3.11.1. B .3 (IV) French Ovarian Cancer Biomarkers Market	382
3.11.1. B .3 (V) Spanish Ovarian Cancer Biomarkers Market	383
3.11.1. B .3 (VI) Swiss Ovarian Cancer Biomarkers Market	383
3.11.1. B .3 (VII) Belgian Ovarian Cancer Biomarkers Market	383
3.11.1. B .3 (VIII) Swedish Ovarian Cancer Biomarkers Market	383
3.11.1. B .3 (IX) Russian Ovarian Cancer Biomarkers Market	383
3.11.1. B .4 Asia-Pacific Ovarian Cancer Biomarkers Market	384
Exhibit 50. Ovarian Cancer Biomarkers – Asia-Pacific Market Estimations and Predictions (2005-2020) in US$ Million for Japan, China, India, Australia, South Korea and Asia-Pacific	384
Exhibit 51. Ovarian Cancer Biomarkers – Asia-Pacific Market Shares (2010, 2015 & 2020) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific	385
3.11.1. B .4 (I) Japanese Ovarian Cancer Biomarkers Market	385
3.11.1. B .4 (II) Chinese Ovarian Cancer Biomarkers Market	385
3.11.1. B .4 (III) Indian Ovarian Cancer Biomarkers Market	385
3.11.1. B .4 (IV) Australian Ovarian Cancer Biomarkers Market	385
3.11.1. B .4 (V) South Korean Ovarian Cancer Biomarkers Market	385
3.11.1. B .5 Rest of World Ovarian Cancer Biomarkers Market	386
Exhibit 52. Ovarian Cancer Biomarkers – Rest of World Market Estimations and Predictions (2005-2020) in US$ Million for Israel, South Africa, Brazil and Other Countries	386
Exhibit 53. Ovarian Cancer Biomarkers – Rest of World Market Shares (2010, 2015 & 2020) for Israel, South Africa, Brazil and Other Countries	387
3.11.1. B .5 (I) Israeli Ovarian Cancer Biomarkers Market	387
3.11.1. B .5 (II) South African Ovarian Cancer Biomarkers Market	387
3.11.1. B .5 (III) Brazilian Ovarian Cancer Biomarkers Market	387
3.11.1. C BREAST CANCER	388
3.11.1. C.1 Global Breast Cancer Biomarkers Market	388
Exhibit 54. Breast Cancer Biomarkers – Global Market Estimations and Predictions (2005-2020) in US$ Million for North America, Europe, Asia-Pacific and Rest of World	388
Exhibit 55. Breast Cancer Biomarkers – Global Market Shares (2010, 2015 & 2020) for North America, Europe, Asia-Pacific and Rest of World	389
3.11.1. C.2 North American Breast Cancer Biomarkers Market	390
Exhibit 56. Breast Cancer Biomarkers– North American Market Estimations and Predictions (2005-2020) in US$ Million for USA and Canada	390
Exhibit 57. Breast Cancer Biomarkers – North American Market Shares (2010, 2015 & 2020) for USA and Canada	391
3.11.1. C.2 (I) United States Breast Cancer Biomarkers Market	391
3.11.1. C.2 (II) Canadian Breast Cancer Biomarkers Market	391
3.11.1. C.3 European Breast Cancer Biomarkers Market	392
Exhibit 58. Breast Cancer Biomarkers– European Market Estimations and Predictions (2005-2020) in US$ Million for Germany, UK, Italy, France, Spain, Switzerland, Belgium, Sweden, Russia and Rest of Europe	392
Exhibit 59. Breast Cancer Biomarkers – European Market Shares (2010, 2015 & 2020) for Germany, UK, Italy, France, Spain, Switzerland, Belgium, Sweden, Russia and Rest of Europe	393
3.11.1. C.3 (I) German Breast Cancer Biomarkers Market	393
3.11.1. C.3 (II) United Kingdom Breast Cancer Biomarkers Market	393
3.11.1. C.3 (III) Italian Breast Cancer Biomarkers Market	393
3.11.1. C.3 (IV) French Breast Cancer Biomarkers Market	393
3.11.1. C.3 (V) Spanish Breast Cancer Biomarkers Market	394
3.11.1. C.3 (VI) Swiss Breast Cancer Biomarkers Market	394
3.11.1. C.3 (VII) Belgian Breast Cancer Biomarkers Market	394
3.11.1. C.3 (VIII) Swedish Breast Cancer Biomarkers Market	394
3.11.1. C.3 (IX) Russian Breast Cancer Biomarkers Market	394
3.11.1. C.4 Asia-Pacific Breast Cancer Biomarkers Market	395
Exhibit 60. Breast Cancer Biomarkers – Asia-Pacific Market Estimations and Predictions (2005-2020) in US$ Million for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific	395
Exhibit 61. Breast Cancer Biomarkers – Asia-Pacific Market Shares (2010, 2015 & 2020) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific	396
3.11.1. C.4 (I) Japanese Breast Cancer Biomarkers Market	396
3.11.1. C.4 (II) Chinese Breast Cancer Biomarkers Market	396
3.11.1. C.4 (III) Indian Breast Cancer Biomarkers Market	396
3.11.1. C.4 (IV) Australian Breast Cancer Biomarkers Market	396
3.11.1. C.4 (V) South Korean Breast Cancer Biomarkers Market	396
3.11.1. C.5 Rest of World Breast Cancer Biomarkers Market	397
Exhibit 62. Breast Cancer Biomarkers – Rest of World Market Estimations and Predictions (2005-2020) in US$ Million for Israel, South Africa, Brazil and Other Countries	397
Exhibit 63. Breast Cancer Biomarkers – Rest of World Market Shares (2010, 2015 & 2020) for Israel, South Africa, Brazil and Other Countries	398
3.11.1. C.5 (I) Israeli Breast Cancer Biomarkers Market	398
3.11.1. C.5 (II) South African Breast Cancer Biomarkers Market	398
3.11.1. C.5 (III) Brazilian Breast Cancer Biomarkers Market	398
3.11.1. D LUNG CANCER	399
3.11.1. D.1 Global Lung Cancer Biomarkers Market	399
Exhibit 64. Lung Cancer Biomarkers – Global Market Estimations and Predictions (2005-2020) in US$ Million for North America, Europe, Asia-Pacific and Rest of World	399
Exhibit 65. Lung Cancer Biomarkers – Global Market Shares (2010, 2015 & 2020) for North America, Europe, Asia-Pacific and Rest of World	400
3.11.1. D.2 North American Lung Cancer Biomarkers Market	401
Exhibit 66. Lung Cancer Biomarkers– North American Market Estimations and Predictions (2005-2020) in US$ Million for USA and Canada	401
Exhibit 67. Lung Cancer Biomarkers – North American Market Shares (2010, 2015 & 2020) for USA and Canada	402
3.11.1. D.2 (I) United States Lung Cancer Biomarkers Market	402
3.11.1. D.2 (II) Canadian Lung Cancer Biomarkers Market	402
3.11.1. D.3 European Lung Cancer Biomarkers Market	403
Exhibit 68. Lung Cancer Biomarkers– European Market Estimations and Predictions (2005-2020) in US$ Million for Germany, UK, Italy, France, Spain, Switzerland, Belgium, Sweden, Russia and Rest of Europe	403
Exhibit 69. Lung Cancer Biomarkers – European Market Shares (2010, 2015 & 2020) for Germany, UK, Italy, France, Spain, Switzerland, Belgium, Sweden, Russia and Rest of Europe	404
3.11.1. D.3 (I) German Lung Cancer Biomarkers Market	404
3.11.1. D.3 (II) United Kingdom Lung Cancer Biomarkers Market	404
3.11.1. D.3 (III) Italian Lung Cancer Biomarkers Market	404
3.11.1. D.3 (IV) French Lung Cancer Biomarkers Market	404
3.11.1. D.3 (V) Spanish Lung Cancer Biomarkers Market	405
3.11.1. D.3 (VI) Swiss Lung Cancer Biomarkers Market	405
3.11.1. D.3 (VII) Belgian Lung Cancer Biomarkers Market	405
3.11.1. D.3 (VIII) Swedish Lung Cancer Biomarkers Market	405
3.11.1. D.3 (IX) Russian Lung Cancer Biomarkers Market	405
3.11.1. D.4 Asia-Pacific Lung Cancer Biomarkers Market	406
Exhibit 70. Lung Cancer Biomarkers – Asia-Pacific Market Estimations and Predictions (2005-2020) in US$ Million for Japan, China, India, Australia, South Korea and Asia-Pacific	406
Exhibit 71. Lung Cancer Biomarkers – Asia-Pacific Market Shares (2010, 2015 & 2020) for Japan, China, India, Australia, South Korea and Asia-Pacific	407
3.11.1. D.4 (I) Japanese Lung Cancer Biomarkers Market	407
3.11.1. D.4 (II) Chinese Lung Cancer Biomarkers Market	407
3.11.1. D.4 (III) Indian Lung Cancer Biomarkers Market	407
3.11.1. D.4 (IV) Australian Lung Cancer Biomarkers Market	407
3.11.1. D.4 (V) South Korean Lung Cancer Biomarkers Market	407
3.11.1. D.5 Rest of World Lung Cancer Biomarkers Market	408
Exhibit 72. Lung Cancer Biomarkers – Rest of World Market Estimations and Predictions (2005-2020) in US$ Million for Israel, South Africa, Brazil and Other Countries	408
Exhibit 73. Lung Cancer Biomarkers – Rest of World Market Shares (2010, 2015 & 2020) for Israel, South Africa, Brazil and Other Countries	409
3.11.1. D.5 (I) Israeli Lung Cancer Biomarkers Market	409
3.11.1. D.5 (II) South African Lung Cancer Biomarkers Market	409
3.11.1. D.5 (III) Brazilian Lung Cancer Biomarkers Market	409
3.11.1. E OTHER CANCERS	410
3.11.1. E.1 Global Other Cancer Biomarkers Market	410
Exhibit 74. Other Cancer Biomarkers – Global Market Estimations and Predictions (2005-2020) in US$ Million for North America, Europe, Asia-Pacific and Rest of World	410
Exhibit 75. Other Cancer Biomarkers – Global Market Shares (2010, 2015 & 2020) for North America, Europe, Asia-Pacific and Rest of World	411
3.11.1. E.2 North American Other Cancers Biomarkers Market	412
Exhibit 76. Other Cancers Biomarkers– North American Market Estimations and Predictions (2005-2020) in US$ Million for USA and Canada	412
Exhibit 77. Other Cancers Biomarkers – North American Market Shares (2010, 2015 & 2020) for USA and Canada	413
3.11.1. E.3 European Other Cancers Biomarkers Market	414
Exhibit 78. Other Cancers Biomarkers– European Market Estimations and Predictions (2005-2020) in US$ Million for Germany, UK, Italy, France, Spain, Switzerland, Belgium, Sweden, Russia and Rest of Europe	414
Exhibit 79. Other Cancers Biomarkers – European Market Shares (2010, 2015 & 2020) for Germany, UK, Italy, France, Spain, Switzerland, Belgium, Sweden, Russia and Rest of Europe	415
3.11.1. E.4 Asia-Pacific Other Cancers Biomarkers Market	416
Exhibit 80. Other Cancers Biomarkers – Asia-Pacific Market Estimations and Predictions (2005-2020) in US$ Million for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific	416
Exhibit 81. Other Cancers Biomarkers – Asia-Pacific Market Shares (2010, 2015 & 2020) for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific	417
3.11.1. E.5 Rest of World Other Cancers Biomarkers Market	418
Exhibit 82. Other Cancers Biomarkers – Rest of World Market Es

To request a free sample copy of this report, please complete the form below.

Enter captcha code*

We never share your personal data. Privacy policy